Skip to content
Screener

Beam Therapeutics BEAM Total Current Liabilities

Total Current Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$3.94B-4.8%
Arrowhead Research logo
Arrowhead ResearchARWR
$295.22M+33.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$351M+19.7%
MGN
MagniteMGNI
$1.7B-3.5%
Wave Life Sciences logo
Wave Life SciencesWVE
$50.82M-41.9%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$79.39M-16.9%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$2.81B+52.0%
Enterprise value$2.78B+61.1%
P/S17.2×-13.6×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:22 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210338
Line itemMarch 31,2026December 31,2025
Current portion of deferred revenue3046,659
Current portion of lease liability14,78114,364
Current portion of contingent consideration liabilities2,7032,714
Total current liabilities74,56596,935
Long-term lease liability135,848139,759
Long-term portion of contingent consideration liabilities5,4495,952
Long-term portion of debt100,193
Other liabilities305173

Item 1. Financial Statements (Unaudited)

FAQ

What is Beam Therapeutics's total current liabilities?
Beam Therapeutics (BEAM) reported total current liabilities of $74.57M in Q1 2026.
How has Beam Therapeutics's total current liabilities changed year-over-year?
Beam Therapeutics's total current liabilities decreased by 47.3% year-over-year, from $141.55M to $74.57M.
What is the long-term trend for Beam Therapeutics's total current liabilities?
Over 5 years (2020 to 2025), Beam Therapeutics's total current liabilities has grown at a -1.1% compound annual growth rate (CAGR), from $102.34M to $96.94M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.

Ask your AI about Beam Therapeutics's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude